September 20, 2022
Renovacor, Inc. Investigation
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Renovacor, Inc. (“Renovacor” or the “Company”) (NYSE:RCOR), in connection with the proposed acquisition of the Company by Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals”) (NASDAQ: RCKT). Under the terms of the merger agreement, the Company’s shareholders will receive 0.1676 shares of Rocket Pharmaceuticals common stock for each Renovacor share owned, representing implied per-share merger consideration of approximately $2.34 based upon Rocket Pharmaceuticals’ September 19, 2022 closing price of $13.97.
Join Case →